All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag

(Bloomberg) -- The deal sweetener that Bristol Myers Squibb Co. offered as a part of its bid to buy Celgene Corp. plunged after management said U.S. regulators have not scheduled an inspection of a...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.